Biotech News

Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance

Moleculin Biotech, Inc. (MBRX)Moleculin Biotech, Inc.Clinical readout

Patent protection spans North America, Europe & Asia-Pacific Rim

Korean decision to grant extends reconstitution protection into another key Asia-Pacific market, reinforcing a multi-layered portfolio spanning more than 20 jurisdictions as pivotal Phase 3 MIRACLE trial advances

Related news

LYELLyell Immunopharma2026-11-04 14:01 EST

Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma

BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST

Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026

GERNGeron2026-10-28 12:00 EST

Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis

JNJJohnson & Johnson2026-10-25 14:24 EST

Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer

BNTXBioNTech2026-10-22 10:45 EST

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

JNJJohnson & Johnson2026-10-19 12:23 EST

Johnson & Johnson announces new TREMFYA® (guselkumab) data showing durable 3-year outcomes in moderate to severe Crohn’s disease and expanding evidence in perianal fistula

ELVNEnliven Therapeutics2026-10-14 20:30 EST

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

BMYBMYBristol-Myers Squibb Company2026-10-12 10:50 EST

Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

REGNRegeneron Pharmaceuticals2026-11-19 12:00 EST

Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH)

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

Moleculin Biotech, Inc.

Late-Stage Oncology Pipeline Moleculin Biotech is a clinical-stage company developing treatments for difficult-to-treat cancers and viral diseases. Its portfolio centers on Annamycin in acute myeloid leukemia, supported by earlier-stage programs targeting oncogenic transcription and tumor metabolism. Annamycin Annamycin is a...

Recent company news

Stock data

Close
7.93 USD
Market cap
13.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States